Gufic Biosciences Promotes Two Senior Management Personnel

Date: September 02, 2026

Designation Change: Promoted from Company Secretary, Compliance Officer and Senior Manager – Legal to Company Secretary, Compliance Officer and Head-Legal
Effective Date: September 02, 2026
Qualifications: Qualified Company Secretary and holds a degree in Law (LL.B.)
Experience: Associated with the Company for over 10 years, previously joined as Company Secretary & Compliance Officer and Executive - Legal
Expertise: Extensive experience in corporate secretarial affairs, corporate governance, statutory and regulatory compliances under Companies Act 2013, Listing Regulations and other applicable laws. Substantial experience in handling legal matters including drafting, reviewing and negotiating domestic and international commercial agreements, litigation and court matters, legal notices, and providing legal advisory on pharmaceutical business matters. Management of intellectual property matters including trademarks. Previously associated with JM Baxi Group as Senior Executive – Secretarial Team.
Continuing Roles: Retains positions as Company Secretary & Compliance Officer, Key Managerial Personnel of the Company

Designation Change: Promoted from Vice President – Sales & Marketing to President – Sales & Marketing
Effective Date: September 02, 2026
Qualifications: Pharmacy Graduate with an MBA in Marketing
Experience: Seasoned pharmaceutical sales and marketing professional with over 28 years of leadership experience in the pharmaceutical industry
Previous Companies: Worked with leading pharmaceutical organizations including Sun Pharma, Ranbaxy, Glenmark, Elder, Medley and Cadila Pharma
Expertise: Broad-based experience in sales, marketing, brand management and business development. Handled portfolios across multiple therapeutic areas including Orthopaedics, Gastrointestinal, Gynaecology, Herbal, Dermatology, Pediatrics and General Practice. Core areas include strategic brand building, product cluster growth, product launches, market expansion and management of multi-therapy portfolios.

The Board of Directors approved the promotions via Circular Resolution passed on September 02, 2026
Decisions were based on the recommendation of the Nomination & Remuneration Committee
The intimation is made pursuant to Regulation 30 read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Compliance with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

No relationships between directors disclosed (Not Applicable for both appointments)
The disclosure is made under Regulation 30 of the Listing Regulations